Targeting Aurora B kinase potentially has a dual antitumor role, by directly inhibiting migration and growth of cells and as enhancer of vemurafenib efficacy in BRAF(V600K) melanoma and of nab-paclitaxel based chemotherapy in BRAF wild type and mutated melanoma. This evidence concerns the gene AURKB and melanoma.